The Right Drug or Trial for Every Patient. This is the OmniSeq Mission.

OmniSeq® was founded with one purpose in mind: To inform physicians and their patients of the most actionable tumor-profiling information possible. We know that, when we accomplish this goal, we’re enabling patients to benefit from personalized treatment that will help them fight their illness at a molecular level.

At Omniseq®, we advance personalized medicine by focusing solely on the improvement of patient outcomes.

This is Who We Are.

Founded in 2015, OmniSeq® is a commercial, CAP accredited, CLIA and New York State CLEP licensed clinical laboratory in Buffalo, New York. We utilize next generation sequencing (NGS) technologies through New York State CLEP approved comprehensive molecular profiling, as well as offer a wide variety of pharmaceutical services to assist in drug development.

This is Our Legacy.

Roswell Park Comprehensive Cancer Center in Buffalo, New York is a pioneer clinical research facility for advanced treatment of all forms of adult and pediatric cancer, and a Member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center’s Founder, Dr. Roswell Park, sought to cure cancer and advocated a close connection between laboratory and clinical research to speed up discovery, and Roswell Park Comprehensive Cancer Center was the first institution to focus exclusively on cancer research.

After more than a century, Roswell Park Comprehensive Cancer Center continues to be at the forefront of groundbreaking cancer research. The institute’s history includes initiating the first experiments in chemotherapy in 1904; becoming America’s first Comprehensive Cancer Center; and providing the source, RP11 (RP stands for Roswell Park), for much of the BAC clone library used in the Human Genome Project.

OmniSeq® emerged from the Roswell Park Comprehensive Cancer Center’s Center of Personalized Medicine, and the breakthrough research, scientific expertise, and commitment to improving patient care define what OmniSeq® is today.

Dr. Carl Morrison, Founder of OmniSeq® and Executive Director of the Center for Personalized Medicine at Roswell Park Comprehensive Cancer Center, first envisioned the role of more advanced bioinformatics in clinical decision support while working at Roswell Park.

OmniSeq Laboratory Team

Carl Morrison, MD, DVM

President, CMO, Laboratory Director and Founder

Dr. Morrison is OmniSeq’s President and Chief Medical Officer. Dr. Morrison is a board-certified pathologist and SVP, Scientific Development and Integrative Medicine at Roswell Park Comprehensive Cancer Center.  Dr. Morrison is a Professor and Program Member in Cancer Genetics at Roswell Park Comprehensive Cancer Center and was awarded Roswell Park’s prestigious Thomas B. Tomasi Hope Award for his contribution to cancer research.

Jeffrey Conroy

Jeffrey Conroy

Chief Scientific Officer

Jeffrey Conroy serves as Chief Scientific Officer for OmniSeq. He oversees the scientific functions of OmniSeq, including Research and Development (R&D), Bioinformatics and Information Technology.  He leads business development activities with key industry and pharmaceutical partners, and oversees the development and implementation of advanced diagnostic tests from target design through analytical validation.  Prior to joining OmniSeq, Jeff spent three years as Director of Genomic Technologies in the Center for Personalized Medicine at Roswell Park Comprehensive Cancer Center.

OmniSeq Executive Team

Margot Schoenborn

Chief Executive Officer

Margot Schoenborn serves as Chief Executive Officer and a member of the Board of Directors.  She is responsible for leading corporate strategy and oversight of all commercial and corporate functions, while partnering with the Company’s President & CMO and Chief Scientific Officer to enable OmniSeqto realize the potential of its genomic testing and next-generation sequencing (NGS) assays in clinical and research settings. 

Paul DePietro, PhD

Executive Director, Knowledge Informatics

Paul DePietro leads the design and development of the OmniSeq Knowledgebase that serves targeted therapy, immunotherapy, and clinical trial information to OmniSeq clinical and research products.

Keith DiPirro

Executive Director, Sales

Keith DiPirro leads commercial operations as OmniSeq’s Executive Director of Sales. With over 18 years in the medical sales industry, Keith heads up sales operations for OmniSeq and leads the sales efforts in collaboration with OmniSeq’s exclusive channel partner.

Sean Glenn

VP of Clinical and Research Development

Dr. Glenn is responsible for leadership of the R&D staff which is responsible for identifying and developing the next level of clinical tests needed to service the oncology field.

Sarah Howath

Executive Director, Payer and Client Relations

Sarah Howarth leads the managed care, billing and customer service functions for OmniSeq and has over 15 years of healthcare experience leading billing and customer service teams.

Mary K. Nesline

SVP, Clinical Evidence Development

As SVP of Clinical Evidence Development, Mary Nesline establishes and executes measurement strategies and studies that support clinical utility for the OmniSeq product portfolio, supports product reimbursement and distribution strategies, and leverages OmniSeq testing assets for external pharmaceutical and academic business development.

Daria Shanchuk, CPA, MBA

Executive Director, Finance

Daria Shanchuk leads the finance and budgeting functions for OmniSeq and has over 20 years of accounting and management experience.

Yirong Wang

Executive Director, Bioinformatics and IT

Yirong Wang leads bioinformatics development, information technology infrastructure and software development for OmniSeq clinical and research products.

OmniSeq Board of Directors

Steven M. Anderson, PhD

Chief Scientific Officer-Covance, Sr VP, LabCorp

Dr. Anderson is a Senior Vice President at Laboratory Corporation of America (LabCorp), and the Chief Scientific Officer for the Covance Drug Development business of LabCorp. He has been with the LabCorp organization for 26 years and has held a variety of positions including Director of Operations for ViroMed Laboratories.

 

Paul Billings, MD, Ph.D, FACP, FACGMP

Chief Medical Officer, Natera

Paul Billings, MD, Ph.D, FACP, FACGMP is a Board certified internist and clinical geneticist. Dr. Billings is the Chairman of Biological Dynamics, Inc., an innovative cancer testing company in San Diego, CA and is also the CMO of Natera.

Marcia Eisenberg, PhD

Chief Scientific Officer and SVP, LabCorp

Marcia Eisenberg, PhD is Chief Scientific Officer and Senior Vice President at LabCorp Diagnostics. Dr. Eisenberg earned a BS in biology, a BA in psychology, and an MS in molecular biology from the State University of New York at Albany. She completed her PhD in molecular biology from the University of Kentucky.

Mark Gardner, MBA

Senior Vice President, Corza Health

Mark Gardner is the Senior Vice President of Business Development for Corza Health. Prior to this role Mark served as the Chief Executive Officer of OmniSeq. Mark has spent over twelve years in various executive roles at Thermo Fisher Scientific (previously Life Technologies).

Mark was the Vice President and General Manager of the Ion Torrent business unit at Thermo Fisher. Prior to Thermo Fisher, Mark was a Six Sigma Master Black Belt at General Electric, an entrepreneur at two start-up companies, a management consultant at McKinsey and Company, and a Navy Pilot.

Kenneth A. Manning

Partner, Phillips Lytle LLP

Kenneth A. Manning is a partner with Phillips Lytle LLP, with experience in corporate litigation, personal injury litigation and class actions that is represented by his status as member emeritus for the Dean’s Advisory Council of University at Buffalo Law School. Mr. Manning was recognized as “Lawyer of the Year” in bet-the-company litigation on the prestigious The Best Lawyers in America 2019 list and has served on OmniSeq’s Board since 2015.

Carl Morrison, MD, DVM

President, CMO, Laboratory Director and Founder

Carl Morrison is a board-certified pathologist, who developed the vision for OmniSeq while leading the Center for Personalized Medicine and Division of Molecular Pathology at RPCCC.

Margot Schoenborn, Esq.

Chief Executive Officer, OmniSeq

Margot Schoenborn is the Chief Executive Officer with experience in corporate development, transactions, capital market activities, corporate finance, and leadership of multi-functional teams over a nearly 20 year career in healthcare, law enforcement, and commercial litigation.

R. Buford Sears

R. Buford Sears has held various management positions for banks, most recently as KeyBank’s Regional President for Western New York, in charge of commercial lending. He is a member of the board of directors of Roswell Park Comprehensive Cancer Center, chairs the Roswell Park’s Finance Committee, and has vast expertise in commercial real estate and equipment financing, healthcare and government banking activities. Mr. Sears earned a BA in International Studies from the University of North Carolina at Chapel Hill and an MA in International Economics from Johns Hopkins University. Mr. Sears has served on OmniSeq’s Board of Directors since 2015.